Introduction {#Sec1}
============

Inflammation plays an important role in all stages of atherosclerosis \[[@CR1]\]. Markers of inflammation are often used to assess cardiovascular risk, and sometimes guide decisions regarding the treatment of atherosclerotic coronary heart disease (CHD) \[[@CR1], [@CR2]\]. Upon vascular injury, vascular endothelial cells express vascular adhesion molecules (such as intercellular adhesion molecule-1 \[ICAM-1\]), that facilitate attachment of circulating leukocytes and promote vascular inflammation, which may help explain the observed association of vascular adhesion molecules with increased CHD risk \[[@CR3], [@CR4]\]. Concurrently, lipoprotein particles such as low-density lipoproteins (LDL) may collect within the intima, where they can undergo oxidation and create unstable oxygen free radicals and other reactive oxygen species \[[@CR5]\]. Increased plasma concentrations of oxidized LDL (Ox-LDL) are thought to help predict future CHD events \[[@CR6]\].

Lipoprotein-associated phospholipase A~2~ (Lp-PLA~2~) is an enzyme brought into the arterial intima bound to LDL particles; it may also be produced by plaque inflammatory cells \[[@CR7], [@CR8]\]. Lp-PLA~2~ facilitates enzymatic modification of Ox-LDL particles, hydrolyzing Ox-LDL phospholipids to lysophosphatidylcholine and oxidized free fatty acids, which subsequently activate inflammatory macrophages \[[@CR8]\]. Ox-LDL activation of macrophages can also increase interleukin-6 (IL-6), which may increase adhesion molecule expression, thus promoting vascular inflammation and potentially worsening atherosclerotic progression \[[@CR9]\]. In clinical practice, the potential contribution of inflammation to atherosclerosis is most often assessed by C-reactive protein (CRP), an acute-phase reactant. CRP is produced by the liver and various other non-hepatic tissues such as vascular smooth muscle cells \[[@CR10]\]. Increased CRP can be found with inflammatory diseases, as well as in overweight individuals as a response to increased IL-6 from dysfunctional adipose tissue \[[@CR11]\]. Low-grade increases in CRP levels may also occur in response to increased inflammatory signaling from vascular macrophages associated with atherosclerosis \[[@CR10]\]. Clinical trials have found levels of Lp-PLA~2~ and CRP to be higher in patients who developed CHD and ischemic stroke compared to those who did not experience these cardiovascular events \[[@CR12], [@CR13]\].

Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are omega-3 fatty acids found in fish oil and in supplements and prescription formulations \[[@CR14]\]. Therapeutically, EPA and DHA lower triglyceride (TG) levels and may reduce cardiovascular events \[[@CR15]\]. Icosapent ethyl (IPE; Vascepa^TM^ \[formerly AMR101\]; Amarin, Bedminster, NJ, USA) is a high-purity prescription form of EPA ethyl ester approved by the US Food and Drug Administration (FDA) as an adjunct to diet to reduce TG levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. MARINE ([M]{.ul}ulti-Center, Pl[A]{.ul}cebo-Controlled, [R]{.ul}andomized, Double-Bl[IN]{.ul}d, 12-week study with an open-label [E]{.ul}xtension) evaluated the efficacy and safety of IPE in lowering TG levels in 229 patients with very high TG levels (≥500 mg/dL and ≤2000 mg/dL). In MARINE, patients were allowed to continue with their statin therapy if they were deemed to have a high risk for CHD or CHD risk equivalents and were on a stable dose. ANCHOR evaluated the efficacy and safety of IPE in lowering TG levels in 702 statin-treated patients at high cardiovascular risk with well-controlled LDL-C and residually high TG levels (≥200 mg/dL and \<500 mg/dL). In both studies, IPE 4 g/day significantly lowered TG, non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (apo B), very-low-density lipoprotein cholesterol (VLDL-C), and total cholesterol (TC) levels, all without significantly raising LDL-C levels \[[@CR16], [@CR17]\]. This current analysis describes the effects of IPE on the a priori secondary and exploratory endpoints of the circulating inflammatory markers ICAM-1, Ox-LDL, Lp-PLA~2~, IL-6, and high-sensitivity CRP (hsCRP) observed in MARINE and ANCHOR.

Methods {#Sec2}
=======

Design and Patients {#Sec3}
-------------------

MARINE (NCT01047683) and ANCHOR (NCT01047501) study designs were previously published \[[@CR16], [@CR17]\]. Briefly, both were phase III, placebo-controlled, randomized, double-blind, multicenter studies with a 4- to 6-week lead-in period of diet, lifestyle, and medication stabilization with washout of prohibited lipid-altering medications. In both studies, eligible men and women aged \>18 years with qualifying lipid levels (MARINE: TG ≥500 mg/dL and ≤2000 mg/dL; ANCHOR: TG ≥200 mg/dL and \<500 mg/dL and LDL-C ≥40 mg/dL and \<115 mg/dL) entered a 12-week double-blind treatment period and were randomized to receive either IPE 4 g/day, IPE 2 g/day, or matched placebo.

Statistical Analysis {#Sec4}
--------------------

The primary efficacy endpoint for MARINE and ANCHOR was the median placebo-adjusted percentage change in TG levels from baseline to study end (week 12) in the two active treatment groups. All efficacy analyses were performed on the intent-to-treat (ITT) population, defined as all randomized patients who had a baseline efficacy measurement, received ≥1 dose of study drug, and had ≥1 post-randomization efficacy measurement. The efficacy endpoints reported here include median placebo-adjusted percentage changes from baseline to week 12 in ICAM-1, Ox-LDL, Lp-PLA~2~, IL-6, and hsCRP levels for IPE (both doses) compared to placebo. All were exploratory variables except for Lp-PLA~2~, which was a secondary variable. In MARINE, inflammation-related endpoints were evaluated in nearly all patients; in ANCHOR, ICAM-1, Ox-LDL, and IL-6 were measured in approximately the first 240 patients of the ITT population.

The median difference of each variable in this analysis (percentage change from baseline) between each IPE treatment group and the placebo group was evaluated with a non-parametric test using the Hodges-Lehmann medians of the differences between treatment groups and the Wilcoxon rank-sum test (data were non-parametric in distribution). For the exploratory endpoints assessed in this analysis, a *p* value alpha of ≤0.05 was prespecified and no adjustments were made for multiple comparisons; adjustments were made for multiple comparisons for Lp-PLA~2~ as this was a prespecified secondary endpoint (the *p*-values were adjusted by applying Hommel's multiple comparison procedure to control the Type I error as pre-specified in the study protocol). All statistical analyses were carried out using SAS software version 8.2 or higher (SAS Institute, Cary, NC, USA). Note that the two-sample Hodges-Lehmann median does not estimate the difference of the means or the difference of the medians; it estimates the median of the differences, which, if the underlying distributions are asymmetric, is a different quantity (i.e., the Hodges-Lehmann median of the differences between treatment groups does not exactly match the numerical difference between the two medians of the treatment groups).

Laboratory Measurements {#Sec5}
-----------------------

Serum concentrations of ICAM-1 were measured using a Quantikine^®^ Human sICAM-1 enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN, USA). Plasma Ox-LDL concentrations were measured with a solid-phase two-site enzyme immunoassay (Mercodia, Winston Salem, NC, USA). Serum IL-6 concentrations were measured using the Luminex fluorescent microsphere technology. Serum Lp-PLA~2~ and hsCRP were measured as previously described \[[@CR16]\]. All assays were performed by Medpace Reference Laboratories (Cincinnati, OH, USA; Navi, Mumbai, India; and Leuven, Belgium) except for the Lp-PLA~2~ assay, which was performed by Berkeley HeartLab (Burlingame, CA, USA).

Results {#Sec6}
=======

Patient Characteristics {#Sec7}
-----------------------

Table [1](#Tab1){ref-type="table"} includes the baseline demographics of patients in the randomized populations of MARINE and ANCHOR, and Table [2](#Tab2){ref-type="table"} lists the baseline lipid parameters in the ITT populations. Baseline demographics and lipid parameters were comparable among treatment groups within each study. A higher percentage of patients in ANCHOR (73 %) had diabetes mellitus than in MARINE (28 %), reflecting that ANCHOR was a high CHD risk population. Differences in baseline lipid parameters between the studies were reflective of the different lipid entry criteria. In MARINE, 55 % of the randomized patients were at high risk for CHD; in ANCHOR, all patients were required to have clinical CHD or CHD risk equivalents (10-year risk ≥20 %).Table 1Patient characteristics (randomized populations) \[[@CR16], [@CR17]\]CharacteristicMARINEANCHORIPE 4 g/day (*n* = 77)IPE 2 g/day (*n* = 76)Placebo (*n* *=* 76)IPE 4 g/day (*n* = 233)IPE 2 g/day (*n* = 236)Placebo (*n* = 233)Age, years \[mean (SD)\]51.9 (10.27)53.4 (9.34)53.4 (8.34)61.1 (10.03)61.8 (9.42)61.2 (10.05)Male \[n (%)\]59 (76.6)58 (76.3)58 (76.3)142 (60.9)144 (61.0)145 (62.2)White \[n (%)\]67 (87.0)67 (88.2)68 (89.5)226 (97.0)226 (95.8)224 (96.1)Weight, kg \[mean (SD)\]93.2 (18.27)92.1 (15.57)93.0 (16.92)94.5 (18.30)95.5 (18.29)97.0 (19.14)BMI, kg/m^2^ \[mean (SD)\]30.4 (4.29)30.8 (4.24)31.0 (4.25)32.7 (4.99)32.9 (4.98)33.0 (5.04)Diabetes \[n (%)\]22 (28.6)20 (26.3)21 (27.6)171 (73.4)172 (72.9)171 (73.4)Baseline TG \>750 mg/dL \[n (%)\]29 (37.7)29 (38.2)32 (42.1)NANANAStatin use \[n (%)\]^**a**^ Any20 (26.0)19 (25.0)18 (23.7)233 (100)236 (100)233 (100) AtorvastatinNANANA44 (18.9)43 (18.2)45 (19.3) SimvastatinNANANA134 (57.5)136 (57.6)133 (57.1) RosuvastatinNANANA55 (23.6)57 (24.2)55 (23.6)Statin efficacy regimens \[n (%)\]^b^ LowerNANANA16 (6.9)17 (7.2)15 (6.4) MediumNANANA148 (63.5)148 (62.7)144 (61.8) HigherNANANA69 (29.6)71 (30.1)74 (31.8)^a^24.9 % (57/229) of patients in the MARINE study were on statin therapy^b^Lower-efficacy statin regimens = simvastatin 5--10 mg; medium-efficacy statin regimens = rosuvastatin 5--10 mg, atorvastatin 10--20 mg, simvastatin 20--40 mg, simvastatin 10--20 mg + ezetimibe 5--10 mg; higher-efficacy statin regimens = rosuvastatin 20--40 mg, atorvastatin 40--80 mg, simvastatin 80 mg, simvastatin 40--80 mg + ezetimibe 5--10 mg*BMI* body mass index, *NA* data not applicable to study design, *SD* standard deviation, *TG* triglycerideTable 2Baseline lipid parameters (intent-to-treat populations) \[[@CR16], [@CR17]\]Lipid parameter (mg/dL)MARINEANCHORIPE 4 g/day (IQR) (*n* *=* 77)IPE 2 g/day (IQR) (*n* *=* 76)Placebo (IQR) (*n* *=* 76)IPE 4 g/day (IQR) (*n* *=* 233)IPE 2 g/day (IQR) (*n* *=* 236)Placebo (IQR) (*n* *=* 233)TG679.5 (265.3) (*n* *=* 76)656.5 (303.5) (*n* *=* 73)703.0 (426.5) (*n* *=* 75)264.8 (93.0) (*n* *=* 226)254.0 (92.5) (*n* *=* 234)259.0 (81.0) (*n* *=* 227)LDL-C90.5 (42.5) (*n* *=* 76)84.0 (58.0) (*n* *=* 73)86.0 (58.0) (*n* *=* 75)82.0 (25.0) (*n* *=* 225)82.0 (24.0) (*n* *=* 233)84.0 (27.0) (*n* *=* 226)Non-HDL-C225.0 (89.5) (*n* *=* 76)210.0 (75.0) (*n* *=* 73)229.0 (85.0) (*n* *=* 75)128.0 (32.0) (*n* *=* 226)128.0 (33.0) (*n* *=* 234)128.0 (34.0) (*n* *=* 227)TC253.5 (86.5) (*n* *=* 76)236.0 (79.0) (*n* *=* 73)256.0 (97.0) (*n* *=* 75)167.0 (38.0) (*n* *=* 226)169.0 (34.0) (*n* *=* 234)168.0 (38.0) (*n* *=* 227)HDL-C26.5 (10.0) (*n* *=* 76)26.0 (6.0) (*n* *=* 73)27.0 (8.0) (*n* *=* 75)37.0 (12.0) (*n* *=* 226)38.0 (13.0) (*n* *=* 234)39.0 (12.0) (*n* *=* 227)Data are presented as median (interquartile range \[IQR\])*HDL-C* high-density lipoprotein cholesterol, *LDL-C* low-density lipoprotein cholesterol, *TC* total cholesterol, *TG* triglyceride

Circulating Markers of Inflammation {#Sec8}
-----------------------------------

Compared to placebo, IPE 4 g/day significantly decreased several circulating markers of inflammation (Fig. [1](#Fig1){ref-type="fig"} and Table [3](#Tab3){ref-type="table"}). In ANCHOR, IPE significantly decreased Ox-LDL (13 %; *p* *\<* 0.0001) and Lp-PLA~2~ levels (19 %; *p* \< 0.0001 \[[@CR17]\]), and in MARINE, IPE significantly decreased Lp-PLA~2~ levels (14 %; *p* \< 0.001 \[[@CR16]\]). IPE 2 g/day did not significantly decrease levels of these markers of inflammation, except for Lp-PLA~2~, for which IPE 2 g/day produced a significant reduction in ANCHOR (8.0 %; *p* \< 0.0001 \[[@CR17]\]). Baseline hsCRP levels were elevated in all groups (ranging from 1.8 to 2.2 mg/L; Table [3](#Tab3){ref-type="table"}). IPE 4 g/day significantly decreased hsCRP levels by 36 % (*p* \< 0.01) in MARINE and by 22 % (*p* \< 0.001) \[[@CR17]\] in ANCHOR. IPE did not cause significant changes in ICAM-1 or IL-6 levels.Fig. 1Median placebo-adjusted percentage change from baseline to week 12 in levels of inflammatory markers (intent-to-treat population). Lp-PLA~2~ data for MARINE from Bays et al. \[[@CR16]\], Lp-PLA~2~ and hsCRP data for ANCHOR from Ballantyne et al \[[@CR17]\]. *P* values for Lp-PLA~2~ were adjusted for multiple comparisons. *hsCRP* high-sensitivity C-reactive protein, *ICAM-1* intercellular adhesion molecule-1, *IL-6* interleukin-6, *IPE* icosapent ethyl, *Lp-PLA*~*2*~ lipoprotein-associated phospholipase A~2,~*NS* not significant, *Ox-LDL* oxidized low-density lipoprotein. \**p* *\<* 0.01; ^†^*p* \< 0.001; ^‡^*p* *\<* 0.0001 vs. placeboTable 3Median placebo-adjusted percentage change from baseline to study end in circulating markers of inflammation (intent-to-treat populations)IPE 4 g/dayIPE 2 g/dayPlaceboMedian placebo-adjusted % change from baselineBaseline valueEnd-of-treatment valueChange from baseline, %Baseline valueEnd-of-treatment valueChange from baseline, %Baseline valueEnd-of-treatment valueChange from baseline, %IPE 4 g/day vs placebo, *p*IPE 2 g/day vs placebo, *p*MARINE*n* *=* 76*n* *=* 73*n* *=* 75 ICAM-1, ng/mL (*n* *=* 75, 70, 72)250.0\
(85.00)253.0\
(89.00)−0.9\
(10.69)255.5\
(86.00)257.5\
(102.00)−0.4\
(12.29)247.5\
(101.00)246.0\
(89.50)2.6\
(13.43)−2.5\
0.1188−2.3\
0.2201 Ox-LDL, U/L (*n* *=* 74, 70, 71)76.2\
(32.30)74.5\
(39.60)−6.9\
(26.28)71.0\
(29.50)71.9\
(29.30)2.7\
(24.19)76.5\
(39.30)75.3\
(37.20)2.5\
(22.73)−6.6\
0.0548−1.4\
0.6665 Lp-PLA~2~, ng/mL (*n* *=* 73, 70, 70) \[[@CR16]\]246.0\
(116.00)201.0\
(100.00)−17.1\
(24.43)235.0\
(106.00)220.5\
(101.00)−5.1\
(24.14)253.0\
(126.00)256.0\
(146.00)−2.4\
(29.35)−13.6\
0.0003−5.1\
0.1529 IL-6, pg/mL (*n* *=* 60, 62, 61)2.3\
(3.34)2.4\
(3.32)0.3\
(93.07)3.0\
(2.78)3.0\
(5.39)3.4\
(76.70)2.5\
(4.12)2.3\
(1.85)5.3\
(79.27)11.0\
0.36294.7\
0.6654 hsCRP, mg/L (*n* *=* 75, 70, 72)2.2\
(3.10)2.2\
(2.90)−2.5\
(81.19)2.0\
(2.70)2.4\
(3.20)25.1\
(96.43)1.8\
(3.05)2.5\
(3.95)33.3\
(80.49)−36.0\
0.0012−10.1\
0.4028ANCHOR*n* *=* 226*n* *=* 234*n* *=* 227 ICAM-1, ng/mL (*n* *=* 78, 74, 83)273.0\
(96.00)270.0\
(110.00)0.8\
(13.27)267.0\
(97.00)268.5\
(89.00)0.5\
(12.41)269.0\
(122.00)257.0\
(131.00)3.6\
(12.07)−2.4\
0.1888−2.2\
0.1944 Ox-LDL, U/L (*n* *=* 78, 75, 84)54.0\
(14.60)51.4\
(17.50)−4.8\
(19.63)54.0\
(17.80)55.8\
(22.80)2.6\
(18.28)51.8\
(16.80)59.7\
(18.10)11.6\
(28.09)−13.3\
\< 0.0001−5.8\
0.0946 Lp-PLA~2~, ng/mL (*n* *=* 217, 224, 213) \[[@CR17]\]180.0\
(56.00)160.0\
(57.00)−12.8\
(18.52)190.0\
(55.50)183.5\
(57.50)−1.8\
(23.11)185.0\
(58.00)200.0\
(71.00)6.7\
(24.03)−19.0\
\< 0.0001−8.0\
\< 0.0001 IL-6, pg/mL (*n* *=* 78, 74, 83)2.7\
(2.61)2.6\
(2.08)3.1\
(56.47)2.4\
(2.01)2.7\
(2.28)6.9\
(51.85)3.2\
(3.23)2.9\
(2.95)3.3\
(59.37)−1.0\
0.90317.0\
0.3643 hsCRP, mg/L (*n* *=* 217, 227, 219) \[[@CR17]\]2.2\
(2.70)2.0\
(3.00)−2.4\
(62.75)1.9\
(2.90)2.5\
(3.40)10.3\
(88.61)2.2\
(4.00)2.6\
(4.70)17.1\
(107.99)−22.0\
0.0005−6.8\
0.2894Only subjects with non-missing baseline and week 12 values are included. Data are presented as median (interquartile range \[IQR\]) for endpoint values. *p* values for Lp-PLA~2~ were adjusted for multiple comparisons*hsCRP* high-sensitivity C-reactive protein, *ICAM-1* intercellular adhesion molecule-1, *IL-6* interleukin-6, *Lp-PLA*~*2*~ lipoprotein-associated phospholipase A~2~, *Ox-LDL* oxidized low-density lipoprotein

hsCRP Statin Use Subgroup Analyses {#Sec9}
----------------------------------

Table [4](#Tab4){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"} show that the changes from baseline for IPE 4 g/day and placebo in hsCRP in patients not treated with statins in the MARINE trial were 0.0 % and 31 %, respectively, resulting in a statistically significant placebo-adjusted reduction of 27 % (*p* = 0.0311). The changes from baseline in hsCRP in patients treated with statins for IPE 4 g/day and placebo were −31 and 43 %, respectively, resulting in a statistically significant placebo-adjusted reduction of 68 % (*p* = 0.0098). In ANCHOR, the changes from baseline in hsCRP for IPE 4 g/day and placebo in patients treated with atorvastatin were −12 and 31 %, respectively, resulting in a statistically significant placebo-adjusted reduction of 37 % (*p* = 0.0475). The changes from baseline in hsCRP for IPE 4 g/day and placebo in patients treated with rosuvastatin were −1.2 % and 15.2 %, respectively, resulting in a statistically significant placebo-adjusted reduction of 31 % (*p* = 0.0217). The changes from baseline in hsCRP for IPE 4 g/day and placebo in patients treated with simvastatin were 0.0 and 13.2 %, respectively, resulting in a statistically non-significant placebo-adjusted reduction of 13.6 % (*p* = 0.0755). Compared to placebo in ANCHOR, IPE 4 g/day significantly decreased hsCRP levels in patients receiving higher- (29 %, *p* \< 0.05) and medium- (23 %, *p* \< 0.01) but not lower-efficacy statin regimens (+4 %). However, the number of patients receiving IPE 4 g/day in the lower-efficacy statin treatment group was smaller (*n* = 16) than those in the medium- (*n* = 132) and higher- (*n* = 69) efficacy statin treatment groups. IPE 2 g/day did not significantly decrease hsCRP in the subgroups analyzed. Excluding the small numbers of subjects per group with hsCRP levels \>10 mg/L did not alter the conclusions on hsCRP lowering.Table 4Median placebo-adjusted percentage change from baseline to study end in high-sensitivity C-reactive protein (mg/L; intent-to-treat population subgroups)IPE 4 g/dayIPE 2 g/dayPlaceboMedian placebo-adjusted % change from baselineBaseline valueEnd-of-treatment valueChange from baseline, %Baseline valueEnd-of-treatment valueChange from baseline, %Baseline valueEnd-of-treatment valueChange from baseline, %IPE 4 g/day vs. placebo, *p*IPE 2 g/day vs. placebo, *p*MARINE*n* *=* 76*n* *=* 73*n* *=* 75Statin use No statin (*n* *=* 56, 52, 55)2.2\
(3.05)2.2\
(2.55)0.0\
(92.15)2.2\
(2.40)2.5\
(3.15)31.7\
(81.50)1.8\
(2.50)2.4\
(3.60)30.8\
(86.11)−27.4\
0.0311−2.7\
0.8297 Statin (*n* *=* 19, 18, 17)1.9\
(3.60)1.3\
(3.80)−30.6\
(80.13)1.5\
(3.30)1.6\
(2.20)11.7\
(169.12)1.8\
(3.20)3.5\
(4.10)42.9\
(75.00)−67.9\
0.0098−33.2\
0.1707ANCHOR*n* *=* 226*n* *=* 234*n* *=* 227Statin type Atorvastatin (*n* *=* 38, 42, 44)2.1\
(2.70)1.5\
(3.00)−11.7\
(100.00)1.7\
(2.70)2.3\
(3.50)20.1\
(80.75)1.6\
(3.55)2.2\
(5.35)30.8\
(117.86)−36.7\
0.0475−9.3\
0.6563 Rosuvastatin (*n* *=* 52, 53, 52)2.6\
(3.05)1.9\
(3.55)−1.2\
(68.87)1.6\
(1.90)2.0\
(2.30)0.0\
(90.95)2.5\
(4.50)2.9\
(6.35)15.2\
(112.74)−31.4\
0.0217−11.0\
0.3922 Simvastatin (*n* *=* 127, 132, 123)2.2\
(2.70)2.2\
(2.80)0.0\
(61.57)2.2\
(3.90)2.7\
(3.50)11.0\
(88.18)2.2\
(3.80)2.6\
(3.80)13.2\
(93.33)−13.6\
0.0755−3.8\
0.6562Statin efficacy regimen^a^ Lower (*n* *=* 16, 15, 14)2.1\
(2.65)2.4\
(2.45)11.9\
(45.47)1.5\
(2.20)1.7\
(2.70)13.3\
(89.74)2.4\
(2.70)2.6\
(1.90)15.7\
(75.56)4.0\
0.884310.2\
0.6467 Medium (*n* *=* 132, 145, 134)2.2\
(2.95)1.8\
(3.60)−7.7\
(63.96)2.3\
(4.00)2.6\
(3.40)8.7\
(76.67)2.2\
(4.00)2.6\
(5.30)15.3\
(90.80)−22.8\
0.0034−8.3\
0.2839 Higher (*n* *=* 69, 67, 71)2.5\
(2.80)2.0\
(2.70)0.0\
(78.97)1.7\
(2.10)2.2\
(3.10)16.7\
(99.32)2.2\
(3.30)2.6\
(4.40)28.6\
(124.36)−28.6\
0.0210−8.3\
0.5227Only subjects with non-missing baseline and week 12 values are included. Data are presented as median (interquartile range \[IQR\]) for endpoint values^a^Lower-efficacy statin regimens = simvastatin 5--10 mg; medium-efficacy statin regimens = rosuvastatin 5--10 mg, atorvastatin 10--20 mg, simvastatin 20--40 mg, simvastatin 10--20 mg + ezetimibe 5--10 mg; higher-efficacy statin regimens = rosuvastatin 20--40 mg, atorvastatin 40--80 mg, simvastatin 80 mg, simvastatin 40--80 mg + ezetimibe 5--10 mgFig. 2Median placebo-adjusted percentage change from baseline to week 12 in hsCRP levels for statin use subgroups (intent-to-treat population). **a** MARINE; **b** and **c** ANCHOR. *IPE* icosapent ethyl, *Lower-efficacystatin regimens* simvastatin 5--10 mg, *medium-efficacy statin regimens* rosuvastatin 5--10 mg, atorvastatin 10--20 mg, simvastatin 20--40 mg, simvastatin 10--20 mg + ezetimibe 5--10 mg, *higher-efficacy statin regimens* rosuvastatin 20--40 mg, atorvastatin 40--80 mg, simvastatin 80 mg, simvastatin 40--80 mg + ezetimibe 5--10 mg, *NS* not significant. \**p* \< 0.05; ^†^*p* \< 0.01 vs. placebo

Discussion {#Sec10}
==========

IPE (formerly AMR101) is a high-purity prescription form of EPA ethyl ester approved by the FDA as an adjunct to diet to reduce TG levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. MARINE evaluated IPE in patients with very high TG levels (≥500 mg/dL and ≤2000 mg/dL) with and without statin therapy \[[@CR16]\] and ANCHOR evaluated IPE in statin-treated patients with residually high TG (≥200 mg/dL and \<500 mg/dL) \[[@CR17]\]. Both these studies demonstrated that, compared to placebo, IPE lowered TG, non-HDL-C, apo B, VLDL-C, and TC levels without significantly raising LDL-C levels \[[@CR16], [@CR17]\].

Compared to placebo in MARINE, IPE 4 g/day substantially decreased hsCRP levels more in the statin-treated patients (68 %) than in patients not receiving statin therapy (27 %) (Table [4](#Tab4){ref-type="table"}). Compared to placebo in ANCHOR, IPE 4 g/day decreased hsCRP levels by 37, 31, and 14 % in patients taking atorvastatin, rosuvastatin, and simvastatin, respectively. In ANCHOR, IPE 4 g/day significantly decreased median placebo-adjusted Ox-LDL levels by 13 % (*p* \< 0.0001). In MARINE and ANCHOR, respectively, IPE 4 g/day significantly decreased median placebo-adjusted Lp-PLA~2~ by 14 % (*p* \< 0.001) \[[@CR16]\] and 19 % (*p* \< 0.0001) \[[@CR17]\] and hsCRP levels by 36 % (*p* \< 0.01) and 22 % (*p* \< 0.001) \[[@CR17]\]. IPE did not significantly change ICAM-1 or IL-6. Statins are known to decrease hsCRP levels \[[@CR18], [@CR19]\], and subjects in both MARINE and ANCHOR who received statin therapy were on stable therapy prior to administration of IPE. Thus, the effects of IPE on inflammatory markers in this study were in addition to effects already achieved with statins. It is of interest that in ANCHOR, IPE decreased hsCRP more in higher-efficacy statin regimens.

Prior reports of EPA and/or DHA effects on LDL oxidation \[[@CR20], [@CR21]\] or CRP \[[@CR22]--[@CR30]\] are inconsistent. As is standard for reporting efficacy in placebo-controlled clinical trials, and as per the statistical analyses defined for this study, all measured efficacy parameters including hsCRP and Ox-LDL were in comparison to placebo. Placebo-adjusted comparisons between groups were based upon median values, because TG and the other measured parameters are commonly non-parametric, especially when evaluated in patients with high or very high TG levels. Despite variability inherent in these non-parametric parameters, the data shown in Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"} support that IPE 4 g/day (the dose approved for clinical use) consistently decreased or resulted in no change from baseline in hsCRP or Ox-LDL, and significantly decreased hsCRP relative to the placebo groups. Compared to placebo, IPE 4 g/day consistently decreased hsCRP in patients treated with or without statins, and among different statins and different statin doses. The only exception was seen in patients receiving lower-efficacy statin regimens, for whom IPE 4 g/day resulted in a mild increase in hsCRP, which was not statistically significant and was numerically lower than the increase seen with placebo. Some reports suggest consumption of omega-3 fatty acids has little effect on Lp-PLA~2~ levels in healthy patients \[[@CR31], [@CR32]\]. However, the data in this analysis are consistent with the prior finding that when 4 g per day of a prescription omega-3 fatty acid (containing both EPA and DHA) were added to stable statin therapy in hypertriglyceridemic patients, Lp-PLA~2~ levels were decreased \[[@CR33]\].

Clinically, the degree by which LDL particles bind to and are internalized by LDL receptors may be somewhat dependent upon the LDL particle oxidation. Circulating LDL particles with minimal oxidative modification may continue to be recognized and internalized by body tissue (such as liver) LDL receptors, while extensively oxidized LDL particles may be less able to bind to LDL receptors \[[@CR34]\]. Conversely, oxidized LDL particles may undergo preferential uptake by macrophage scavenger receptors, which are not regulated by cellular cholesterol content \[[@CR34]\]. In the subendothelial space, the cholesterol-laden macrophages may be transformed into foam cells, which are commonly found within atherosclerotic lesions \[[@CR34]\]. The net result is that the decreased recognition of circulatory Ox-LDL by LDL receptors may contribute to increased circulating LDL-C levels, while the increased uptake of Ox-LDL by subendothelial macrophages may promote accumulation and death of foam cells, endothelial toxicity, and promotion of atherogenesis.

Given that other omega-3 fatty acid therapies of EPA and DHA in hypertriglyceridemic patients may (substantially) increase LDL-C levels \[[@CR35], [@CR36]\], the lack of LDL-C increases in MARINE and ANCHOR may be explained by the lack of DHA in IPE. It is possible that the decrease in LDL oxidation with IPE (albeit a non-significant reduction in MARINE) observed in this analysis may increase LDL receptor recognition and may play a role in the lack of rise in LDL-C levels in MARINE and perhaps contribute to the decrease in LDL-C levels found in ANCHOR.

The potential clinical significance of the anti-inflammatory effects of IPE may be supported by JELIS (Japan EPA Lipid Intervention Study), wherein administration of 1.8 g/day of \>98 % EPA ethyl ester (Mochida Pharmaceuticals, Tokyo, Japan) reduced major coronary events in Japanese hypercholesterolemic patients receiving statin therapy \[[@CR37]\] despite only marginal differences in LDL-C, HDL-C, and TG levels between the EPA + statin and statin-alone groups \[[@CR37], [@CR38]\]. Possible mechanisms wherein omega-3 fatty acids may reduce CHD include anti-inflammatory effects \[[@CR15]\].

Limitations of this analysis include that: (i) all endpoints were exploratory, with the exception of Lp-PLA~2~, which was a secondary endpoint in both studies; (ii) patients were not selected based upon elevated baseline inflammatory marker levels, which may have limited the ability to detect significant changes in some inflammatory markers (e.g., IL-6 and ICAM-1); and (iii) ICAM-1, Ox-LDL, and IL-6 were measured in a subset of the ANCHOR ITT population and thus may lack statistical power to detect significant changes. Additionally, neither MARINE nor ANCHOR were of a design, or of sufficient size, to assess cardiovascular disease outcomes. To this end, the ongoing REDUCE-IT (Reduction of Cardiovascular Events with EPA -- Intervention Trial; NCT01492361) will evaluate whether IPE in combination with statin therapy is superior to statin therapy alone in the reduction of long-term cardiovascular events in approximately 8,000 high-risk patients with mixed dyslipidemia.

Conclusion {#Sec11}
==========

This follow-up analysis of MARINE and ANCHOR examined the placebo-adjusted effects of IPE (a high-purity prescription form of EPA ethyl ester approved by the FDA as an adjunct to diet to reduce TG levels in adult patients with severe \[≥500 mg/dL\] hypertriglyceridemia) on inflammatory markers associated with cardiovascular disease and atherosclerosis in hypertriglyceridemic patients. In addition to the previously reported favorable lipid effects of IPE \[[@CR16], [@CR17]\], this analysis showed that IPE 4 g/day significantly decreased Ox-LDL, Lp-PLA~2~, and hsCRP levels and thus may offer a combination of beneficial lipid and anti-inflammatory effects.
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